Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223496 · ClinicalTrials.gov registry record · Phase 4
12- Week Open Label Treatment of Refractory Bipolar Depression
A Phase 4 study of Bipolar Disorder, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00223496 is a Phase 4 study of Bipolar Disorder that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 32 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00223496, a Phase 4 study of Bipolar Disorder, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
1. Determine the change in symptomatology and function in refractory bipolar depression, when treated with combination of DEP+AZP for a period of 12 weeks 2. Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (1)
Texas
- Univ of Texas Helath Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223496
The ClinicalTrials.gov registry entry for NCT00223496 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (90% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00223496 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00223496 about?
NCT00223496 is a clinical study titled "12- Week Open Label Treatment of Refractory Bipolar Depression". 1. Determine the change in symptomatology and function in refractory bipolar depression, when treated with combination of DEP+AZP for a period of 12 weeks 2. Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
What is the current status of trial NCT00223496?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2004-09. Estimated completion is 2009-09.
What conditions does trial NCT00223496 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00223496?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00223496?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00223496 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.